Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

A GROUNDBREAKING cancer vaccine could stop tumours growing in patients with advanced disease, researchers say. Designed to ...

In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, ...

It’s better late than never for an FDA approval for the first subcutaneous PD-L1 inhibitor, which was doled out to Roche’s ...

Today we highlight research findings reported at ESMO 2024, the annual meeting of the European Society of Medical Oncology.